Gene Switch / Molecular Switch Market, Share & Trends Analysis Report, Distribution by Application Area (Management of Treatment Related Toxicity, Regulation of Gene Expression), Type of Target Therapy (CAR T Cell Therapy, Gene Therapy), Type of Payment Model Employed, By Region, and Segment Forecasts, 2024-2031
The Gene Switch / Molecular Switch Market Size is valued at USD 0.69 Bn in 2023 and is predicted to reach USD 1.44 Bn by the year 2031 at an 9.9% CAGR during the forecast period for 2024-2031. Gene switches are locations on genes that are capable of binding regulatory molecules to start the transcription and translation processes that result in the expression of that particular gene. Gene switching pertains to the reversible on/off regulation ...
Report ID: 2595 |
Delivery: Immediate |
Published: July 2024 |
No. of Pages: 168
Recombinant Human Endostatin Market Size, Share & Trends Analysis Report By Type (purity 95% and others) And By Application (medical care, scientific research and others), By Region, And By Segment Forecasts, 2024-2031
The Recombinant Human Endostatin Market Size is valued at USD 133.3 Mn in 2023 and is predicted to reach USD 249.4 Mn by the year 2031 at a 8.3% CAGR during the forecast period for 2024-2031. Recombinant human endostatin is a naturally occurring protein in the human body that prevents angiogenesis and has been bioengineered. Genetic engineering methods are used to generate the recombinant form for medical uses. The increasing number of cancer ...
Report ID: 2597 |
Delivery: Immediate |
Published: July 2024 |
No. of Pages: 170
Radionuclide Drug Conjugates (RDC) Market Size, Share & Trends Analysis Distribution by Type (Antibody Radionuclide Conjugates (ARC), Peptide Radionuclide Conjugates (PRC), Small Molecular Radionuclide Conjugates (SMRC)), Disease Indication (Neuroendocrine Tumors, Prostate Cancer, Renal Cell, Carcinoma) and Segment Forecasts, 2024-2031
Radionuclide Drug Conjugates (RDC) Market Size is predicted to witness a 13.9% of CAGR during the forecast period for 2024-2031. Radionuclide Drug Conjugates (RDCs) represent a promising innovation in cancer treatment, utilizing a targeted approach to deliver radiation directly to tumor cells. By combining a radionuclide, targeting molecule, chelator, and linker, RDCs minimize harm to healthy tissues while effectively attacking cancer. This ta...
Report ID: 2567 |
Delivery: Immediate |
Published: July 2024 |
No. of Pages: 180
Disseminated Intravascular Coagulation (DIC) Market Size, Share & Trends Analysis Report By Symptoms (Bleeding, Blood Clots, Bruising, Drop in Blood Pressure, Shortness of Breath, Confusion, Fever), Treatment (Medicines, Transfusions, Surgery), Diagnosis (Complete Blood Count with Blood Smear Exam, Partial Thromboplastin Time (PTT), Prothrombin Time (PT), Fibrinogen Blood Test, D-dimer), Route of Administration, End-Users, Distribution Channel, By Region, And By Segment Forecasts, 2024-2031.
Disseminated Intravascular Coagulation (DIC) Market Size is valued at USD 437.3 Mn in 2023 and is predicted to reach USD 563.8 Mn by the year 2031 at a 3.3% CAGR during the forecast period for 2024-2031. The Disseminated Intravascular Coagulation (DIC) market focuses on managing a serious condition characterized by abnormal blood clotting, involving key segments such as diagnostics (e.g., D-dimer tests), therapeutics (anticoagulants and blood ...
Report ID: 2573 |
Delivery: Immediate |
Published: July 2024 |
No. of Pages: 180
Long Acting Drug Delivery Technologies Services Market Size, Share & Trends Analysis Report By Technique (Long-Acting Injectables, Long-Acting Hydrogels, Long-Acting Implants, Long-Acting Microneedles, And Nanocrystal Suspensions), Dosage Form (Injectables, Implantable, Topical/Transdermal, Vaginal), Type Of Molecule Delivered, Material Used And End-User, Region And Segment Forecasts, 2023-2031
Global Long Acting Drug Delivery Technologies Services Market Size is valued at USD 13.7 Bn in 2023 and is predicted to reach USD 30.2 Bn by the year 2031 at a 10.6% CAGR during the forecast period for 2024-2031. The global long-acting drug delivery technologies and services market is witnessing robust growth due to the demand for improved patient adherence and therapeutic outcomes. Long-acting formulations, including injectables and implants,...
Report ID: 2565 |
Delivery: Immediate |
Published: July 2024 |
No. of Pages: 180
Insulin-like Growth Factors Market Share & Trends Analysis Report, By Type (Mechano Growth Factor, Somatomedin C, IGF 1), By End-user (Hospitals, Medical Centers), By Region, and Segment Forecasts, 2023-2031
Insulin-like Growth Factors Market Size is valued at USD 275.1 Mn in 2023 and is predicted to reach USD 406.1 Mn by the year 2031 at an 5.13% CAGR during the forecast period for 2024-2031. Insulin-like growth factors (IGFs) are proteins that resemble insulin in structure and share some of its effects. Their primary function, however, is to stimulate cell growth and development throughout the body, forming part of a complex system known as the ...
Report ID: 2561 |
Delivery: Immediate |
Published: July 2024 |
No. of Pages: 180
Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Size, Share & Trends Analysis by Disease (Neurological Disorders and Dystrophies, Cardiac disorders, Retinal Eye Disease, Metabolic Disorders, Liver disease, Others), Products and Services (Disease Model, Reprogramming service, Differentiation service, Screening service, Characterization service, Others), and Segment Forecasts, 2023-2031
Human-Induced Pluripotent Stem Cells (hiPSCs) Preclinical Disease Model Market Size is predicted to grow at an 11.2% CAGR during the forecast period for 2024-2031. Human-induced pluripotent stem cells (hiPSCs) are a pivotal tool in biomedical research, particularly for preclinical disease modelling and drug development. Derived from adult somatic cells like skin or blood cells, hiPSCs are reprogrammed to an embryonic-like pluripote...
Report ID: 2556 |
Delivery: Immediate |
Published: July 2024 |
No. of Pages: 180
VEGFR-1 Inhibitors Market Size, Share & Trends Analysis Report, By Drug Type (Monoclonal Antibodies, Tyrosine Kinase Inhibitors, and Others), By Application (Renal Cell Carcinoma, Colorectal Cancer, Non-Small Cell Lung Cancer, and Other), Distribution Channel (Hospital Pharmacies, Retail Pharmacies and Online Pharmacies), By Region, Forecasts, 2024-2031
VEGFR-1 Inhibitors Market Size is predicted to grow at a 7.0% CAGR during the forecast period for 2024-2031. VEGFR-1 inhibitors are essential in treating various cancers by targeting the vascular endothelial growth factor receptor-1, which is crucial for angiogenesis and tumor growth. The increasing prevalence of cancer and advancements in targeted therapies are expected to drive the adoption of VEGFR-1 inhibitors. Additionally, ongoing resear...
Report ID: 2552 |
Delivery: Immediate |
Published: June 2024 |
No. of Pages: 180
Cephalosporin API Market Size, Share & Trends Analysis Report By Product Type (First Generation, Second Generation, Third Generation, Fourth Generation), By Formulation (Oral, Injection), By Consumer Type (Hospital Use, Clinic Use, Recovery Center), By Region, And By Segment Forecasts, 2024-2031.
Cephalosporin API Market Size is valued at USD 1.70 billion in 2023 and is predicted to reach USD 2.62 billion by the year 2031 at a 5.7% CAGR during the forecast period for 2024-2031. Cephalosporin APIs are the active pharmaceutical ingredients derived from fungi, specifically Acremonium, and they form the basis of cephalosporin antibiotics like cephalexin and ceftriaxone. These APIs are crucial for treating bacterial infections and undergo r...
Report ID: 2547 |
Delivery: Immediate |
Published: June 2024 |
No. of Pages: 180
Thymidylate Synthase Inhibitor Market Size, Share & Trends Analysis Report By Type (Injection, Tablet, Others), By Application (Hospital, Clinic, Others), By Region, And By Segment Forecasts, 2024-2031.
Thymidylate Synthase Inhibitor Market Size is predicted to grow at a 6.0% CAGR during the forecast period for 2024-2031. Thymidylate synthase inhibitors disrupt DNA synthesis by blocking the enzyme thymidylate synthase. They are used primarily in cancer treatment to inhibit the growth of cancer cells, which rely on rapid DNA replication. Examples include 5-fluorouracil (administered intravenously), pemetrexed (also intravenous), and raltitrexe...
Report ID: 2549 |
Delivery: Immediate |
Published: June 2024 |
No. of Pages: 180
Pharmaceuticals